文献速递眼底病与葡萄膜炎

PLACE与SPECTRA试验长期随访:半剂量光动力治疗慢性中心性浆液性脉络膜视网膜病变成功与不成功的结局

Long-Term Follow-Up of PLACE and SPECTRA Trials: Outcomes After Successful and Unsuccessful Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
PubMed 文献 · Am J Ophthalmol · 2026-03-16

该多中心前瞻性队列研究对PLACE和SPECTRA试验中接受半剂量光动力治疗的慢性中心性浆液性脉络膜视网膜病变患者进行5至10年随访,比较首次治疗成功与不成功者的长期功能与结构结局。结果显示首次治疗成功组长期BCVA更高且黄斑下积液比例更低,但两组BCVA自首次随访后均保持稳定。

要点

  • 首次半剂量PDT成功者长期BCVA更高,黄斑下积液比例更低。
  • 两组BCVA自半剂量PDT后首次随访起均保持稳定。
  • 首次PDT不成功者随访期间追加治疗比例较高。

核心结论

  • 首次半剂量PDT成功的cCSC患者长期临床结局优于首次治疗不成功者。
  • 两组自半剂量PDT后首次随访起BCVA均保持稳定,即使初始治疗未成功者亦如此。

研究设计与样本

  • 多中心前瞻性队列研究,纳入PLACE和SPECTRA试验中接受半剂量PDT的cCSC患者。

主要发现

  • 首次半剂量PDT成功78例、不成功29例。
  • 随访期间因SRF复发或持续,成功组14.1%、不成功组89.7%接受追加治疗。
  • 长期随访BCVA成功组更高(P < .001);成功组BCVA由81.8 ± 7.8增至87.2 ± 8.7 ETDRS字母(P < .001)。
  • 不成功组BCVA保持稳定(73.4 ± 12.1 vs 77.2 ± 16.2 ETDRS字母,P = .108)。
  • 长期随访时SRF存在于成功组16.7%、不成功组44.8%的眼(P = .005)。

关键数值与推荐

  • 首次半剂量PDT成功组长期BCVA高于不成功组(P < .001)。
  • 长期随访SRF比例成功组16.7% vs 不成功组44.8%(P = .005)。

临床怎么用

  • cCSC患者首次半剂量PDT成功后长期视力结局较好,应积极争取首次治疗成功。
  • 首次PDT未成功者需警惕SRF持续或复发并可能需追加治疗,但视力仍可保持稳定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To prospectively evaluate and compare long-term functional and structural outcomes between successful and unsuccessful first half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (cCSC). DESIGN: Multicenter, prospective cohort study. SUBJECTS, PARTICIPANTS, AND/OR CONTROLS: Participants with cCSC enrolled in the PLACE and SPECTRA trials and treated with half-dose PDT in the participating Dutch medical centers, with visits at 5 to 10 years after inclusion. METHODS, INTERVENTION, OR TESTING: Participants were randomly assigned to half-dose PDT, oral eplerenone or high-density subthreshold micropulse laser and had protocol-defined retreatment and/or crossover treatment in case of persistent subretinal fluid (SRF). After 1 to 2 years of follow-up, patients were managed at clinicians' discretion and recalled for a 5 to 10-year visit. MAIN OUTCOME MEASURES: Best-corrected visual acuity (BCVA; measured in Early Treatment of Diabetic Retinopathy Study [ETDRS] letters), retinal sensitivity on microperimetry, presence of macular neovascularization, presence of SRF at long-term follow-up, recurrence of SRF, and retreatment during follow-up. RESULTS: Sixty percent (107/179) of eligible participants completed the long-term follow-up, performed at a median of 7.0 years. The first half-dose PDT was successful in 78 patients and unsuccessful in 29 patients. Due to a recurrence of SRF or persisting SRF, additional treatments were performed in 14.1% and 89.7% of patients in the successful and unsuccessful first PDT group during follow-up, respectively. BCVA at long-term follow-up was higher in the successful first PDT group (P < .001). Between baseline and long-term follow-up, BCVA increased significantly in the successful first PDT group (81.8 ± 7.8 vs 87.2 ± 8.7 ETDRS letters, P < .001), with the highest increase observed between baseline and the first control visit, followed by stabilization of BCVA thereafter. BCVA remained stable in the unsuccessful first PDT group (73.4 ± 12.1 vs 77.2 ± 16.2 ETDRS letters, P = .108). At long-term follow-up SRF was present in 16.7% and 44.8% of eyes in the successful and unsuccessful first PDT group, respectively (P = .005). CONCLUSIONS: cCSC patients with a successful first PDT show better long-term clinical outcomes than those with an unsuccessful first PDT. Notably, BCVA remained stable in both groups from the first follow-up after half-dose PDT onward, which is a reassuring finding even for patients without initial treatment success.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. van den Tillaart FM, Chang-Wolf JM, Feenstra HMA, et al. Long-Term Follow-Up of PLACE and SPECTRA Trials: Outcomes After Successful and Unsuccessful Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Am J Ophthalmol. 2026. PMID: 41850667. doi:10.1016/j.ajo.2026.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。